153 related articles for article (PubMed ID: 30902965)
1. Ubiquitination of MAP1LC3B by pVHL is associated with autophagy and cell death in renal cell carcinoma.
Kang HM; Noh KH; Chang TK; Park D; Cho HS; Lim JH; Jung CR
Cell Death Dis; 2019 Mar; 10(4):279. PubMed ID: 30902965
[TBL] [Abstract][Full Text] [Related]
2. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma.
Mikhaylova O; Stratton Y; Hall D; Kellner E; Ehmer B; Drew AF; Gallo CA; Plas DR; Biesiada J; Meller J; Czyzyk-Krzeska MF
Cancer Cell; 2012 Apr; 21(4):532-46. PubMed ID: 22516261
[TBL] [Abstract][Full Text] [Related]
3. Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma.
An J; Liu H; Magyar CE; Guo Y; Veena MS; Srivatsan ES; Huang J; Rettig MB
Cancer Res; 2013 Feb; 73(4):1374-85. PubMed ID: 23393199
[TBL] [Abstract][Full Text] [Related]
4. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.
Turcotte S; Chan DA; Sutphin PD; Hay MP; Denny WA; Giaccia AJ
Cancer Cell; 2008 Jul; 14(1):90-102. PubMed ID: 18598947
[TBL] [Abstract][Full Text] [Related]
5. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
6. VHL loss predicts response to Aurora kinase A inhibitor in renal cell carcinoma cells.
Ding XF; Zhou J; Chen G; Wu YL
Mol Med Rep; 2018 Jul; 18(1):1206-1210. PubMed ID: 29845253
[TBL] [Abstract][Full Text] [Related]
7. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
9. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
10. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD
Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672
[TBL] [Abstract][Full Text] [Related]
11. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
12. E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis.
Park KS; Kim JH; Shin HW; Chung KS; Im DS; Lim JH; Jung CR
BMC Cancer; 2015 Oct; 15():800. PubMed ID: 26503325
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.
Guo K; Wei Y; Wang Z; Zhang X; Zhang X; Liu X; Wu W; Wu Z; Zhang L; Cui CP
Cell Death Dis; 2022 Feb; 13(2):97. PubMed ID: 35110537
[TBL] [Abstract][Full Text] [Related]
14. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma.
Parker AS; Cheville JC; Lohse CM; Igel T; Leibovich BC; Blute ML
Urology; 2005 Jun; 65(6):1090-5. PubMed ID: 15893810
[TBL] [Abstract][Full Text] [Related]
16. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.
Liu X; Simon JM; Xie H; Hu L; Wang J; Zurlo G; Fan C; Ptacek TS; Herring L; Tan X; Li M; Baldwin AS; Kim WY; Wu T; Kirschner MW; Gong K; Zhang Q
Mol Cell; 2020 Mar; 77(6):1294-1306.e5. PubMed ID: 32023483
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death.
Turcotte S; Sutphin PD; Giaccia AJ
Autophagy; 2008 Oct; 4(7):944-6. PubMed ID: 18769110
[TBL] [Abstract][Full Text] [Related]
20. SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel-Lindau protein ubiquitination and degradation.
Yin R; Liu S
Cancer Sci; 2021 Oct; 112(10):4100-4111. PubMed ID: 34339558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
